Cannabis Pain & Dosage research
Cannabinoids can be used along with opioid medications, and a number of studies have demonstrated that they can reduce the amount of opioids needed, lessen the build-up of tolerance, and reduce the severity of withdrawal. At least ten randomized, controlled trials on over one thousand patients have demonstrated efficacy of cannabinoids for neuropathic pain of various origins. The micro to standard dose is usually recommended to treat pain, but patients need to carefully monitor their condition and experiment to find the right formula; 10–40 mg of CBD or CBD+THC together is usually enough.
Ref - Ethan Russo and Andrea Hohmann, “Role of Cannabinoids in Pain Management,” in Comprehensive Treatment of Chronic Pain by Medical, Interventional and Integrative Approaches, ed. Timothy R. Deer et al. (New York: Springer, 2013), 181–197.
Despite the political and social controversy affiliated with it, the medical community must come to the realization that cannabinoids exist as a ubiquitous signalling system in many organ systems. Our understanding of cannabinoids and how they relate not only to homeostasis but also in disease states must be furthered through research, both clinically and in the laboratory.
Since CBD (cannabidiol) and other compounds in cannabis are so similar to the chemicals created by our own bodies, they are integrated better than many synthetic drugs. According to Bradley E. Alger, a leading scientist in the study of endocannabinoids with a PhD from Harvard in experimental psychology, “With complex actions in our immune system, nervous system, and virtually all of the body’s organs, the endocannabinoids are literally a bridge between body and mind. By understanding this system, we begin to see a mechanism that could connect brain activity and states of physical health and disease.”
A 2012 research review assessed a number of international studies and concluded that CBD had been shown to reduce anxiety, and in particular social anxiety, in multiple studies and called for more clinical trials. Two years later, researchers in an animal study related to stress and the endocannabinoid system wrote that augmentation of the endocannabinoid system might be an effective strategy to mitigate behavioural and physical consequences of stress. In addition to elucidating the relationship between CBD and anxiety, these findings appear to support that the anxiolytic effect of chronic CBD administration in stressed mice depends on its proneurogenic action in the adult hippocampus by facilitating endocannabinoid-mediated signaling.
The Cannabis Health Index (CHI) is an evidence-based scoring system for cannabis (in general, not just CBD oil effects) and its effectiveness on various health issues based on currently available research data. Refer to cannabishealthindex.com for updated information.